Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Scientists identify new way of attacking breast cancer stem cells

Scientists at the University of Michigan Comprehensive Cancer Center have identified a potential new way of attacking breast cancer stem cells, the small number of cells in a tumor that fuel its growth and spread.

18 Jan 2011

Inflammation “master switch” found: Study

According to the latest medical discovery a protein that acts as a “master switch” has been found to determine whether certain white blood cells will boost or dampen inflammation. This may open new avenues in rheumatoid arthritis research. Rheumatoid arthritis or RA is an inflammatory disease that causes severe progressive crippling of the joints.

17 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

New study on being medically prepared for natural disasters

Imagine having to evacuate your home quickly as 60 mph winds shatter your windows, water crawls under your front door and the electricity cuts leaving your house as dark as the inside of a coffee can. Would you be prepared? Now visualize being one of the 56 million Americans with a disability, such as wheelchair dependence, or one of the 133 million with a chronic disease, such as asthma.

11 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

U.S. District Court grants injunction for Sensipar patents

A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.

10 Jan 2011

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Amgen and Xencor, announced today that they will collaborate to develop XmAb®5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

InHealth awards grant to assess effects of hip replacement therapy on aging populations

The Institute for Health Technology Studies has awarded a grant of $240,000 to an international consortium of researchers, for a study that will assess the effects of hip replacement therapy on the employment and retirement decisions of older adults. Led by researchers at the Universit- Bocconi (Milan), the consortium also includes investigators at the University of York (York, UK), and the Johns Hopkins University School of Public Health (Baltimore).

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Mayo Clinic researchers have determined the lifetime risk of developing rheumatoid arthritis and six other autoimmune rheumatic diseases for both men and women. The findings appear online in Arthritis and Rheumatism.

6 Jan 2011

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

For decades, doctors have looked at fitness levels, weight, and overall health risk factors for heart disease and stroke. Now, they may soon add a new risk factor to the list: activation of the complement system. The complement system is usually implicated in immune responses, but now there's a role for it in cardiovascular disease.

5 Jan 2011

Past smoking history does not affect RA patient's response to treatments

Patients with early rheumatoid arthritis (RA) who are current smokers were less likely to achieve good response to methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors than those who never smoked. The study by researchers from Sweden also found that RA patients who smoked in the past did not experience a lower response to these therapies. Results of the 10-year study appear in the January 2011 issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

4 Jan 2011

New research finds pattern for detecting 'false-positive' ANA results

The presence of antinuclear antibodies (ANA) indicates the possibility of autoimmunity and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive" ANA test occurs in up to 13% of healthy individuals. In such cases the test detects the presence of autoantibodies that apparently are not associated with autoimmunity.

4 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

The American Thoracic Society has released a new official clinical policy statement on the treatment of fungal infections in adult pulmonary and critical care patients.

4 Jan 2011

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

29 Dec 2010

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Scientists identify new way of attacking breast cancer stem cells

Inflammation “master switch” found: Study

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

New study on being medically prepared for natural disasters

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

U.S. District Court grants injunction for Sensipar patents

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

InHealth awards grant to assess effects of hip replacement therapy on aging populations

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Anaphylatoxin C5a may be responsible for devastating effects of atherosclerosis

Past smoking history does not affect RA patient's response to treatments

New research finds pattern for detecting 'false-positive' ANA results

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in